(19)
(11) EP 4 577 573 A1

(12)

(43) Date of publication:
02.07.2025 Bulletin 2025/27

(21) Application number: 23856405.8

(22) Date of filing: 31.07.2023
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
C12N 15/13(2006.01)
C12N 5/10(2006.01)
A61P 35/00(2006.01)
 C12N 15/85(2006.01)
C12N 15/63(2006.01)
A61K 39/395(2006.01)
A61P 37/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; A61P 37/00; C07K 16/2803; C07K 2317/24; C07K 2317/92; C07K 2317/76; C07K 2317/74; A61K 2039/507; C07K 2317/732; C07K 16/2818; A61K 2039/505
(86) International application number:
PCT/CN2023/110185
(87) International publication number:
WO 2024/041315 (29.02.2024 Gazette 2024/09)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 22.08.2022 WO PCT/CN2022/114001

(71) Applicant: Antengene Biologics Limited
Shanghai 200051 (CN)

(72) Inventors:
  • BIAN, Gang
    Shanghai 200051 (CN)
  • HUA, Jiahui
    Shanghai 200051 (CN)
  • LIN, Ge
    Shanghai 200051 (CN)
  • CHEN, Peng
    Shanghai 200051 (CN)
  • YUWEN, Hui
    Shanghai 200051 (CN)
  • HOU, Bing
    Shanghai 200051 (CN)
  • SHAN, Bo
    Shanghai 200051 (CN)
  • MEI, Jay
    Shanghai 200051 (CN)

(74) Representative: Simmons & Simmons LLP (Munich) 
Lehel Carré Gewürzmühlstraße 11
80538 Munich
80538 Munich (DE)

   


(54) NOVEL ANTI-LILRB2 ANTIBODIES AND USES THEREOF